How do patients feel about how, when and where they get their myeloma treatment?

Project Launch: April 2023

Myeloma patients may undergo many different types of treatment over the course of their cancer. There is already a high burden on patients due to the myeloma diagnosis, complications, and side-effects of treatment. We need evidence about how patients feel about how treatments are administered (i.e. intravenous, subcutaneous or oral routes of administration) and where (i.e. at home, in the community, or in a hospital). This evidence is critical to informed decision-making and to drive change in industry and regulatory institutions as they consider how drugs should be produced and administered. Understanding how patients feel about how, when and where they get their myeloma treatment is key to efforts to improve patient quality of life and minimise the burden of treatments.

This project aims to explore patients’ perspectives on new and existing treatments for myeloma. Phase one of this project will involve an online survey with myeloma patients throughout Europe. The survey questions will be developed by MPE based on a literature review, analysed and refined by the project steering committee, and piloted with patients. The survey results will support the development of MPE’s future work and research on this topic.

Recruitment status: closed

Please email if you would like to be involved in the pilot testing of the survey, be updated on the project, or have any questions.

Thank you to Pfizer, Sanofi and Takeda for funding this research project.